Organon & Co. (OGN)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 17.98 |
| Open | 17.97 |
| Bid | 17.90 x 1300 |
| Ask | 18.12 x 1300 |
| Day's range | 17.88 - 18.16 |
| 52-week range | 10.84 - 23.10 |
| Volume | |
| Avg. volume | 1,853,575 |
| Market cap | 4.635B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 4.64 |
| EPS (TTM) | 3.88 |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | 1.12 (6.22%) |
| Ex-dividend date | 16 Aug 2024 |
| 1y target est | 23.14 |
ZacksOrganon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Business WireOrganon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
JERSEY CITY, N.J., October 09, 2024--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
Business WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11
© 2024 Yahoo. All rights reserved.